Improving collaboration to expedite early-phase research in oncology
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
What are the consequences of ‘pandemomics’ in gynaecological cancers?
As science and innovations continue to progress in gynaecological oncology, there is a need to rethink our perceptions to ensure clinical management and research advance accordingly
Is combining radiotherapy and immunotherapy a viable treatment option?
Conflicting clinical results on the benefits of combined radiotherapy and immunotherapy may derive from differences in treatment sequencing
Is there still a future for cancer vaccines?
Despite generally disappointing clinical trial results, technological innovations mean that realising the potential for cancer vaccines could be just around the corner
Rare cancers in Asia – the value of registry data in low-resourced settings
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Equity among oncologists is far from being achieved in the Chinese culture
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Current status and future needs with immunotherapy in triple-negative breast cancer
Recent evidence shows the potential of immunotherapy to change the treatment landscape of triple-negative breast cancer (TNBC), where historically, chemotherapy has been the only systemic option. But, how do we choose what therapy to give which patients?